Astellas Pharma Inc. (TYO: 4503) announced that China’s National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for VEOZA (fezolinetant 45 mg), seeking approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. The non-hormonal, selective neurokinin 3 (NK3) receptor antagonist is already approved in 50 countries worldwide, and the NDA acceptance marks a key step toward bringing the therapy to Chinese patients.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Milestone | NDA accepted for review |
| Product | VEOZA (fezolinetant 45 mg), oral |
| Drug Class | Non-hormonal, selective NK3 receptor antagonist |
| Indication Sought | Moderate to severe vasomotor symptoms (VMS) associated with menopause |
| Global Status | Approved in 50 countries |
| Announcement Date | 27 Oct 2026 |
Drug Profile & Mechanism of Action
- Molecule: Fezolinetant, a first-in-class selective neurokinin 3 (NK3) receptor antagonist, administered orally at a 45 mg dose.
- Target Pathway: Blocks neurokinin B binding on kisspeptin/neurokinin/dynorphin (KNDy) neurons, which are involved in regulating the brain’s temperature control center — the hypothalamic circuitry whose hypertrophy during estrogen decline drives hot flashes.
- Therapeutic Effect: By targeting this pathway, fezolinetant helps reduce the frequency and severity of moderate to severe VMS associated with menopause.
- Non-Hormonal Differentiation: As a non-hormonal option, VEOZA addresses patients who cannot take, decline, or are unsuitable for hormone replacement therapy (HRT) — a historically underserved segment in menopause care.
Clinical & Global Context
- Established Track Record: With approvals across 50 countries, fezolinetant’s safety and efficacy profile has been reviewed by major regulators including the U.S. FDA; China-specific trial data were not disclosed in the announcement.
- NDA Review Trajectory: Standard NMPA review timelines apply; a priority or expedited pathway designation was not disclosed.
Market Impact & Outlook
- China Menopause Market: China’s large perimenopausal and postmenopausal population — with historically low HRT uptake due to safety perceptions — represents a substantial commercial opportunity for non-hormonal VMS therapy.
- Category Creation: As one of the first NK3 antagonists to approach the Chinese market, VEOZA could establish the non-hormonal VMS treatment category domestically, ahead of or alongside competing agents in the class.
- Guideline Positioning: Approval would position fezolinetant for inclusion in Chinese menopause management guidelines, supporting specialist-driven adoption across gynecology and menopause clinics.
- Franchise Value: China adds to VEOZA’s global footprint, extending Astellas’s women’s health franchise and diversifying revenue beyond its core oncology and immunology portfolios.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding VEOZA (fezolinetant) in China, including NDA review outcomes, potential approval, and commercialization. NDA acceptance does not guarantee approval; actual results may differ due to risks including regulatory review findings, market adoption, reimbursement decisions, and competitive dynamics in menopause therapy.-Fineline Info & Tech
